Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a placebo-controlled double-blind study of KAN-101 in adults with celiac disease
MOH_2024-04-03_013357Phase 2Active, not recruiting
- Sponsor
- Pfizer
- Start
- Feb 2024
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of KAN-101 in celiac disease, sponsored by Pfizer. Started Feb 2024; status: active, not recruiting.
02
Drugs
KAN-101
03
Conditions
celiac disease
Beyond the preview
Go deeper on MOH_2024-04-03_013357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-04-03_013357.